New Benchmarks for Seminars in Liver Disease

Paul D. Berk

doi:10.1055/s-0032-1329907

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2012; 32(04): 267-270
DOI: 10.1055/s-0032-1329907

Editorial

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Benchmarks for Seminars in Liver Disease

Paul D. Berk

¹Columbia University Medical Center, William Black Medical Research Building, New York, New York

› Author Affiliations

Abstract

Full Text

References

References
1 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
2 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (1) 61-74
3 Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30 (3) 245-257
4 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30 (1) 35-51
5 Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30 (1) 3-16
6 Wu DF, Cederbaum AI. Oxidative stress and alcoholic liver disease. Sem Liver Dis 2009; 29 (2) 141-154
7 Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29 (1) 3-18
8 Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30 (3) 258-270
9 Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30 (2) 134-146
10 Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30 (1) 17-25
11 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29 (4) 400-411
12 Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010; 30 (4) 391-401
13 Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis 2010; 30 (4) 402-410
14 Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009; 29 (3) 241-253
15 Burra P. Hepatitis C. Semin Liver Dis 2009; 29 (1) 53-65
16 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
17 Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28 (1) 81-95
18 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (1) 61-74
19 Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27 (1) 55-76
20 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (3) 329-338
21 Brunt E. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24 (1) 3-20
22 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30 (1) 35-51
23 Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22 (2) 169-184
24 Córdoba J, Mínguez B. Hepatic encephalopathy. Semin Liver Dis 2008; 28 (1) 70-80
25 Ginès P, Cárdenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28 (1) 43-58
26 Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22 (1) 83-96
27 Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25 (2) 212-225
28 Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (S1) 3-10
29 Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28 (1) 26-42
30 Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 370-379
31 Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25 (2) 181-200
32 Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28 (4) 386-395
33 Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30 (1) 3-16
34 Li MK, Crawford JM. The pathology of cholestasis. Semin Liver Dis 2004; 24 (1) 21-42
35 Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 360-369
36 Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 115-125
37 Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29 (4) 412-422
38 Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28 (4) 339-350
39 Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25 (2) 143-154
40 Bernal W, Auzinger G, Sizer E, Wendon J. Intensive care management of acute liver failure. Semin Liver Dis 2008; 28 (2) 188-200
41 Arroyo V, Terra C, Ginès P. New treatments of hepatorenal syndrome. Semin Liver Dis 2006; 26 (3) 254-264
42 Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 75-86
43 Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 396-406
44 Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30 (4) 333-347
45 Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21 (3) 311-336
46 Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29 (1) 3-18
47 Barron L, Wynn T. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30 (3) 245-257
48 Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008; 28 (1) 3-25
49 Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28 (1) 110-122
50 Fontana R. Acute liver failure due to drugs. Semin Liver Dis 2008; 28 (2) 175-187
51 Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30 (1) 17-25
52 Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30 (3) 258-270
53 Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002; 22 (2) 195-206
54 McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 (S1) 3-8
55 Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 87-98
56 Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24 (1) 77-88
57 Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23 (1) 47-58
58 Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28 (1) 59-69
59 Whitington P. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27 (3) 243-250
60 Lee W. Etiologies of acute liver failure. Semin Liver Dis 2008; 28 (2) 142-152
61 Lee W. Acute liver failure in the United States. Semin Liver Dis 2003; 23 (3) 217-226
62 Rutherford A, Chung R. Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis 2008; 28 (2) 167-174
63 Anstee QM, Daly AK, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27 (1) 44-54
64 Plessier A, Valla D-C. Budd-Chiari syndrome. Semin Liver Dis 2008; 28 (3) 259-269
65 André P, Perlemuter G, Budkowska A, Bréchot C, Lotteau V, Hepatitis C. Virus particles and lipoprotein metabolism. Semin Liver Dis 2005; 25 (1) 93-104
66 Bataller R, Brenner D. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21 (3) 437-452
67 DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22 (1) 27-42
68 Jr S. Robert. Acute liver failure in children. Semin Liver Dis 2008; 28 (2) 153-166
69 Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004; 24 (3) 233-247
70 Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006; 26 (4) 385-390
71 Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24 (3) 217-232
72 Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis 2003; 23 (4) 385-396
73 Bioulac-Sage P, Laumonier H, Laurent C, Blanc JF, Balabaud C. Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis 2008; 28 (3) 302-314
74 Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 189-199
75 Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25 (2) 133-142
76 Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21 (3) 397-416
77 Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis 2007; 27 (4) 339-350
78 Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25 (3) 311-320
79 Sozio MS, Liangpunsakul S, Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis 2010; 30 (4) 378-390
80 Sarin SK, Agarwal SR. Extrahepatic portal vein obstruction. Semin Liver Dis 2002; 22 (1) 43-58
81 Marquardt JU, Thorgeirsson SS. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis 2010; 30 (1) 26-34
82 Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003; 23 (3) 259-270
83 Lee J-S, Thorgeirsson SS. Genetic profiling of human hepatocellular carcinoma. Semin Liver Dis 2005; 25 (2) 125-132
84 Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24 (1) 99-106
85 Cheung O, Sanyal AJ. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 351-359
86 Kaplowitz N, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007; 27 (4) 367-377
87 Grompe M. The role of bone marrow stem cells in liver regeneration. Semin Liver Dis 2003; 23 (4) 363-372
88 Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22 (2) 185-194
89 Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21 (3) 351-372
90 Chan HL-Y, Sung JJ-Y. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26 (2) 153-161
91 Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007; 27 (2) 214-226
92 Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27 (2) 152-160
93 Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21 (3) 373-384
94 Afdhal N. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (S2) 3-8
95 Weiss MC, Strick-Marchand H. Isolation and characterization of mouse hepatic stem cells in vitro. Semin Liver Dis 2003; 23 (4) 313-324
96 Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26 (1) 31-41
97 Anderson G, Frazer D. Hepatic iron metabolism. Semin Liver Dis 2005; 25 (4) 420-432
98 Chu C-M, Liaw Y-F, Hepatitis B. Virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26 (2) 142-152
99 Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 139-154
100 DeLeve L. Hepatic microvasculature in liver injury. Semin Liver Dis 2007; 27 (4) 390-400
101 Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005; 25 (2) 171-180
102 Dabeva MD, Shafritz DA. Hepatic stem cells and liver repopulation. Semin Liver Dis 2003; 23 (4) 349-362
103 Pawlotsky J-M. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005; 25 (1) 72-83
104 Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23: 23-28
105 Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23 (1) 39-46
106 Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20 (1) 1-16
107 Brunt E. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21 (1) 3-16
108 Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006; 26 (1) 42-51
109 Asselah T, Bièche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27 (1) 13-27
110 Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004; 24 (2) 155-164
111 Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) Defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007; 27 (1) 77-98
112 Halstead C. Nutrition and alcoholic liver disease. Semin Liver Dis 2004; 24 (3) 289-304
113 Czaja A. Treatment of autoimmune hepatitis. Semin Liver Dis 2002; 22 (4) 365-378
114 Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 2001; 21 (4) 563-572
115 Bolondi L, Burroughs A, Dufour J-F , et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32 (4) 348-359